Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
TK Choueiri, TM Kuzel, SS Tykodi, E Verzoni, H Kluger, S Nair, R Perets, S George, H Gurney, RK Pachynski, E Folefac, V Castonguay, C-H Lee, U Vaishampayan, WH Miller Jr, P Bhagavatheeswaran, Y Wang, S Gupta, H DeSilva, C-W Lee, B Escudier, RJ Motzer · 2024
Read Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial by TK Choueiri, TM Kuzel, SS Tykodi, E Verzoni, H Kluger, S Nair, R Perets, S George, H Gurney, RK Pachynski, E Folefac, V Castonguay, C-H Lee, U Vaishampayan, WH Miller Jr, P Bhagavatheeswaran, Y Wang, S Gupta, H DeSilva, C-W Lee, B Escudier, RJ Motzer (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11667034.txt.
Description
Choueiri and twenty-one co-authors published this trial report in 2024. It tests two immunotherapy pairings as first immune treatment for advanced kidney cancer. Both arms start from nivolumab; one adds relatlimab, which blocks a second immune brake called LAG-3, and the other adds ipilimumab, the established partner.
Thirty patients took each pairing. The relatlimab arm shrank tumors in thirty percent of patients, with responses lasting a median of about eight months. The ipilimumab arm responded in twenty percent, with responses not yet reaching their median length. Freedom from progression at six months was similar. Severe treatment side effects hit thirteen percent on relatlimab against thirty-three percent on ipilimumab. Tumors rich in LAG-3 and PD-L1 markers answered the relatlimab pairing best. The authors judge both pairings active, with the newer one gentler, in this small randomized study.
Catalog record
| CREATOR | TK Choueiri, TM Kuzel, SS Tykodi, E Verzoni, H Kluger, S Nair, R Perets, S George, H Gurney, RK Pachynski, E Folefac, V Castonguay, C-H Lee, U Vaishampayan, WH Miller Jr, P Bhagavatheeswaran, Y Wang, S Gupta, H DeSilva, C-W Lee, B Escudier, RJ Motzer |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |